Loading...
Indian Pharmaceutical Exporter · #1 for Kit · $5.4M export value · DGFT Verified
Lupin Limited is the #1 Indian exporter of Kit with $5.4M in export value and 108 verified shipments. Lupin Limited holds a 1.2% market share in Kit exports across 11 countries. The company exports 38 pharmaceutical products worth $271.4M across 19 therapeutic categories.
| KENYA | $500.4K | 11 | 10.4% |
| PAPUA NEW GUINEA | $200.0K | 4 | 4.1% |
| GHANA | $100.0K | 2 | 2.1% |
| THAILAND | $34.9K | 1 | 0.7% |
| BELGIUM | $2.9K | 9 | 0.1% |
| UNITED STATES | $2.6K | 3 | 0.1% |
Lupin Limited exports Kit to 11 countries. The largest destination is NIGERIA accounting for 38.3% of Lupin Limited's Kit shipments, followed by MYANMAR (18.4%) and INDONESIA (14.5%). These destinations reflect Lupin Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NATIONAL TUBERCULOSIS AND LEPROSY | NIGERIA | $1.1M | 21 |
| SEKRETARIAT DITJEN PENCEGAHAN DAN P | INDONESIA | $650.0K | 13 |
| NATIONAL TUBERCULOSIS AND LEPROSY. | NIGERIA | $550.0K | 11 |
| UNOPS NO 12 O PYITHU LANE 7 MILE | MYANMAR | $400.0K | 8 |
| UNOPS, NO. 12 (O), | MYANMAR | $387.3K | 8 |
| COMMERCIAL BANK OF ETHIOPIA | ETHIOPIA | $350.0K | 7 |
| KENYA MEDICAL SUPPLIES AGENCY | KENYA | $350.0K | 7 |
| NATIONAL TUBERCULOSIS AND LEPROSY C | NIGERIA | $300.0K | 6 |
| NATIONAL DEPARTMENT OF HEALTH | PAPUA NEW GUINEA | $50.0K | 1 |
| UNOPS NO. 12 (O) | MYANMAR | $50.0K | 1 |
Lupin Limited supplies Kit to 24 buyers globally. The largest buyer is NATIONAL TUBERCULOSIS AND LEPROSY (NIGERIA), followed by SEKRETARIAT DITJEN PENCEGAHAN DAN P (INDONESIA) and NATIONAL TUBERCULOSIS AND LEPROSY. (NIGERIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $57.8M worth of Kit through 15,000 shipments from 1048 suppliers to 191 countries, serving 3,293 buyers globally. Lupin Limited contributes $5.4M to this total, accounting for 1.2% of India's Kit exports. Lupin Limited ships Kit to 11 countries through 24 buyers.
Lupin Limited's average Kit shipment value is $50.0K per consignment, based on 108 shipments totaling $5.4M. The largest destination is NIGERIA (38.3% of Lupin Limited's Kit exports).
Lupin Limited ranks #1 among 1048 Indian Kit exporters with a 1.2% market share. The top 3 exporters are SANDOZ PRIVATE LIMITED ($7.8M), MERIL DIAGNOSTICS PRIVATE LIMITED ($5.6M), MICRO LABS LIMITED ($5.5M). Lupin Limited processed 108 shipments to 11 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| STOP TB CAT I & III PATIENT KIT A(GDF)(R | $550.0K | 11 |
| STOP TB CAT I & III PATIENT KIT-A (GDF)RIFAMPICIN 150MG+ ISONIAZIDE 75MG+ PYRAZINAMIDE 400MG+ ETHAMBUTOL 275MG) 6X28TABTBS | $450.0K | 9 |
| STOP TB CAT I & III PATIENT KIT-AGDF RIFAMPICIN 150MG+ISONIAZIDE 75MG+PYRAZINAMIDE 400MG+ETHAMBUTOL 275MG | $400.0K | 8 |
| STOP TB CAT I & III PATIENT KIT-A(GDF)RI | $300.0K | 6 |
| STOP TB CAT I & III PATIENT KIT-A (RIFAM | $250.0K | 5 |
| STOP TB CAT I & III PATIENT KIT-A (GDF)Rifampicin 150mg+ Isoniazide 75mg+ Pyrazinamide 400mg+ Ethambutol*** | $250.0K | 5 |
| STOP TB CAT I & III PATIENT KIT-A ETHIOP | $200.0K | 4 |
| STOP TB CAT I III PATIENT KIT A GDF RI | $200.0K | 4 |
| STOP TB CAT I+II KIT ARIFAMPICIN150MG+ISONIAZID75MG+PYRAZINAMIDE400MG+ETHAMBUTOL275MG6x28T+RIFA.150MG+ISO.75MG12x28T | $200.0K | 4 |
| STOP TB CAT I+II KIT ARIFAMPICIN150MG+ISONIAZID75MG+PYRAZINAMIDE400MG+ETHAMBUTOL275MG6x28T+ RIFA.150MG+ISO.75MG12x28T | $200.0K | 4 |
Lupin Limited exports 47 distinct Kit formulations including tablets, capsules, syrups, and combination drugs. The top formulation is STOP TB CAT I & III PATIENT KIT A(GDF)(R with 11 shipments worth $550.0K.
What Lupin Limited must comply with to export Kit to its top destination countries
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | MERIL DIAGNOSTICS PRIVATE LIMITED | $5.6M | 645 | 64 | $8.7K |
| 9 | MICRO LABS LIMITED | $5.5M | 193 | 22 | $28.5K |
| 1 | LUPIN LIMITED ★ | $5.4M | 108 | 11 | $50.0K |
| 10 | AJANTA PHARMA LIMITED | $5.4M | 339 | 17 | $15.8K |
| 5 | CIPLA LIMITED | $5.3M | 107 | 11 | $50.0K |
Lupin Limited ranks #1 among 1048 Indian Kit exporters. Average shipment value of $50.0K compared to the market average of $55.1K. The closest competitors by value are MERIL DIAGNOSTICS PRIVATE LIMITED and MICRO LABS LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 2,763 | 18.4% |
| SAHAR AIR | 2,534 | 16.9% |
| DELHI AIR CARGO ACC (INDEL4) | 1,051 | 7.0% |
| DELHI AIR | 983 | 6.6% |
| NHAVA SHEVA SEA (INNSA1) | 901 | 6.0% |
| Bombay Air | 541 | 3.6% |
| JNPT/ NHAVA SHEVA SEA | 433 | 2.9% |
| CHENNAI AIR CARGO ACC (INMAA4) | 405 | 2.7% |
Lupin's export operations are influenced by various geopolitical factors. The ongoing Israel-Iran tensions have led to increased security risks in the Red Sea, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, thereby escalating shipping costs for Indian exporters. (sgexports.odoo.com) Additionally, the 2025 United States–India diplomatic and trade crisis resulted in the U.S. imposing a 50% tariff on Indian exports, significantly affecting the competitiveness of Indian pharmaceutical products in the U.S. market. (en.wikipedia.org)
Conversely, the European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) poses compliance challenges for Indian exporters, including Lupin, necessitating adherence to stringent carbon reporting requirements. However, the EU's focus on reducing dependency on Chinese pharmaceutical imports presents an opportunity for Indian companies to capture a larger share of the European market.
Maintaining stringent quality standards is paramount for Lupin's global operations. In February 2025, the U.S. FDA completed a Pre-Approval Inspection at Lupin's Somerset, New Jersey facility with zero observations, reflecting the company's commitment to compliance and quality. (lupin.com) However, the evolving regulatory landscape, including the EU's falsified medicines directive and the U.S. FDA's increasing scrutiny, necessitates continuous investment in quality assurance and regulatory compliance to ensure uninterrupted market access.
Lupin Limited exports 38 products worth $271.4M. Beyond Kit, top products include Isoniazid, Cephalexin, Simvastatin, Rifampicin, Amlodipine. View the complete Lupin Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Kit — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 191+ countries, 3,293+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Lupin Limited's Kit exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Lupin Limited
Full Company Profile →
38 products · $271.4M total trade · 19 categories
Access shipment-level records, pricing trends, and buyer contacts for Lupin Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Kit. For current shipment-level data, contact TransData Nexus.